AGGF1 and neoplasm: This study examined the potential clinical significance of taurolactone, a novel drug renowned for its anti-tumor and anti-angiogenesis properties, particularly concerning angiogenic factor AGGF1 and angiogenesis mimicry in individuals diagnosed with HCC.